Gabriel Holding A/S (CPH:GABR)
Denmark · Delayed Price · Currency is DKK 196.00
+8.00 (4.26%)
Aug 6, 2025, 3:58 PM CET
Theseus Pharmaceuticals Income Statement
Financials in millions DKK. Fiscal year is October - September.
Millions DKK. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2016 - 2020 |
Operating Revenue | 504.11 | 483.48 | 454.54 | 1,065 | 809.71 | 727.3 | Upgrade |
Other Revenue | - | - | - | - | - | 0.18 | Upgrade |
| 504.11 | 483.48 | 454.54 | 1,065 | 809.71 | 727.47 | Upgrade | |
Revenue Growth (YoY) | 147.81% | 6.37% | -57.32% | 31.53% | 11.30% | 2.70% | Upgrade |
Cost of Revenue | 230.57 | 233.4 | 221 | 718.54 | 514.81 | 454.18 | Upgrade |
Gross Profit | 273.53 | 250.09 | 233.54 | 346.48 | 294.89 | 273.3 | Upgrade |
Selling, General & Admin | 198.81 | 194.49 | 186.54 | 239.87 | 198.97 | 193.01 | Upgrade |
Other Operating Expenses | -0.6 | -0.78 | 0.12 | -1.03 | -0.51 | -0.53 | Upgrade |
Operating Expenses | 238.23 | 231.27 | 220.48 | 281.05 | 235.32 | 230.3 | Upgrade |
Operating Income | 35.31 | 18.81 | 13.06 | 65.43 | 59.57 | 43 | Upgrade |
Interest Expense | -14.12 | -16.78 | -13.66 | -5.2 | -4.24 | -3.85 | Upgrade |
Interest & Investment Income | 5.65 | 3.76 | 5.14 | 0.33 | 0.22 | 0.1 | Upgrade |
Earnings From Equity Investments | 2.31 | 0.89 | 0.4 | 0.12 | 2.96 | 2.94 | Upgrade |
Currency Exchange Gain (Loss) | -3.41 | -3.41 | -1.69 | 20.57 | 1.54 | -9.02 | Upgrade |
Other Non Operating Income (Expenses) | -0.14 | -0.14 | -0.16 | -0.15 | -0.34 | -0.06 | Upgrade |
EBT Excluding Unusual Items | 25.6 | 3.14 | 3.09 | 81.1 | 59.72 | 33.11 | Upgrade |
Gain (Loss) on Sale of Assets | 0.39 | 0.39 | 0.05 | -0.15 | 0.11 | -0.51 | Upgrade |
Asset Writedown | 0.47 | 0.47 | 0 | -0.35 | -1.05 | -0.57 | Upgrade |
Pretax Income | 26.46 | 4 | 3.14 | 80.6 | 58.78 | 32.04 | Upgrade |
Income Tax Expense | 3.97 | 5.46 | 4.56 | 22.44 | 12.6 | 7.03 | Upgrade |
Earnings From Continuing Operations | 22.49 | -1.45 | -1.42 | 58.16 | 46.18 | 25 | Upgrade |
Earnings From Discontinued Operations | -30.28 | -14.24 | -42.73 | - | - | - | Upgrade |
Net Income | -7.79 | -15.69 | -44.15 | 58.16 | 46.18 | 25 | Upgrade |
Net Income to Common | -7.79 | -15.69 | -44.15 | 58.16 | 46.18 | 25 | Upgrade |
Net Income Growth | - | - | - | 25.95% | 84.68% | -48.95% | Upgrade |
Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 2 | Upgrade |
Shares Change (YoY) | - | - | - | - | - | -0.06% | Upgrade |
EPS (Basic) | -4.12 | -8.30 | -23.36 | 30.77 | 24.43 | 13.23 | Upgrade |
EPS (Diluted) | -4.16 | -8.33 | -23.36 | 30.77 | 24.40 | 13.20 | Upgrade |
EPS Growth | - | - | - | 26.12% | 84.85% | -49.04% | Upgrade |
Free Cash Flow | 60.78 | 23.36 | 2.8 | -23.06 | 11.57 | 34.5 | Upgrade |
Free Cash Flow Per Share | 32.16 | 12.36 | 1.48 | -12.20 | 6.12 | 18.26 | Upgrade |
Dividend Per Share | - | - | - | 10.750 | 9.750 | 5.000 | Upgrade |
Dividend Growth | - | - | - | 10.26% | 95.00% | -52.38% | Upgrade |
Gross Margin | 54.26% | 51.73% | 51.38% | 32.53% | 36.42% | 37.57% | Upgrade |
Operating Margin | 7.00% | 3.89% | 2.87% | 6.14% | 7.36% | 5.91% | Upgrade |
Profit Margin | -1.55% | -3.25% | -9.71% | 5.46% | 5.70% | 3.44% | Upgrade |
Free Cash Flow Margin | 12.06% | 4.83% | 0.62% | -2.17% | 1.43% | 4.74% | Upgrade |
EBITDA | 63.44 | 42.78 | 34.41 | 83.66 | 71.26 | 56.15 | Upgrade |
EBITDA Margin | 12.58% | 8.85% | 7.57% | 7.85% | 8.80% | 7.72% | Upgrade |
D&A For EBITDA | 28.13 | 23.96 | 21.35 | 18.23 | 11.69 | 13.15 | Upgrade |
EBIT | 35.31 | 18.81 | 13.06 | 65.43 | 59.57 | 43 | Upgrade |
EBIT Margin | 7.00% | 3.89% | 2.87% | 6.14% | 7.36% | 5.91% | Upgrade |
Effective Tax Rate | 15.00% | 136.31% | 145.07% | 27.84% | 21.44% | 21.95% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.